Radioaerosol Pulmonary Deposition During Asthma Exacerbation Through Noninvasive Ventilation (NV)
Despite the physiologic and clinical effects provided by coupling nebulization with noninvasive ventilation in asthma exacerbation, there are few and controversial studies reported in the literature.
|Study Design:||Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation|
- Cardiopulmonary characteristics [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Radioaerosol pulmonary index, radioaerosol penetration index and pulmonary clearance. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2007|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Experimental: NV Group
Performed nebulization coupled with noninvasive ventilation
Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
Other Name: Interventional Group
Active Comparator: NEB group
Performed nebulization alone.
Other: NEB group
Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
Other Name: Control group
Reduced work of breathing, increased oxygenation and increased in expiratory peak flow (EPF) and forced expiratory volume in the first second (FEV1) are benefits of noninvasive ventilation (NV) in the treatment of asthma. Despite these clinical improvements attributed to NV during asthma exacerbations and the well-established effects of nebulization, there are few studies in the literature coupling both therapeutic resources.
In addition to this, no studies on scintigraphic analysis of radioaerosol deposition coupled with NV in asthmatics have published. A previous study was published by our group, but involved healthy subjects.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01012050
|Valdecir Castor Galindo Filho|
|Recife, Pernambuco, Brazil|
|Principal Investigator:||Valdecir C Galindo||Universidade Federal de Pernambuco|